Charles River expands US bioanalysis capabilities with US$470M Frontage acquisition

The acquisition will strengthen Charles River’s ability to support pharmaceutical and biotechnology companies as their development pipelines incorporate more biologics and complex drug modalities.

USA—Charles River Laboratories has agreed to acquire two Frontage laboratory sites in Exton, Pennsylvania, for US$470 million upfront to expand its bioanalysis capabilities and strengthen its drug development services.

Under the agreement announced on November 9, Frontage could receive an additional US$75 million in performance-based payments, bringing the potential transaction value to US$545 million.

The two facilities, located in southeastern Pennsylvania, cover approximately 150,000 square feet and employ around 340 people.

They provide testing services for large and small molecules, including bioanalysis, biomarker analysis, and drug metabolism and pharmacokinetics (DMPK).

Expanding clinical bioanalysis capabilities

The acquisition will strengthen Charles River’s ability to support pharmaceutical and biotechnology companies as their development pipelines incorporate more biologics and complex drug modalities.

Charles River CEO Birgit Girshick said demand for integrated scientific services is increasing as drug developers seek partners capable of supporting programmes from early research through clinical development.

The transaction also supports the company’s strategic vision, known as Pathway to Purpose, which Girshick introduced during its September 2026 investor day.

The strategy aims to reinforce Charles River’s position in early-stage drug development by expanding its regulated testing capabilities across the research and development process.

Girshick described the acquisition as an important step in advancing the strategy through a stronger clinical bioanalysis presence, expanded scientific capabilities and broader support for clients across the drug development lifecycle.

She added that combining the companies’ bioanalysis and DMPK services would create a more integrated offering, helping pharmaceutical developers accelerate timelines and maintain continuity between preclinical and clinical testing.

Tigermed strengthens its global portfolio

Frontage is owned by Chinese contract research organisation (CRO) Tigermed, which provides outsourced clinical development services to pharmaceutical and medical device companies, particularly across China and the Asia-Pacific region.

Tigermed acquired Frontage in 2014 as part of its efforts to expand its international clinical research network.

The sale of the two Pennsylvania facilities transfers their laboratory operations and associated workforce to Charles River, while Tigermed retains its broader clinical development business.

The acquisition reflects continued consolidation and portfolio realignment in the contract research sector, as CROs expand specialised laboratory capabilities to serve increasingly complex drug development programmes.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.

Visited 7 times, 7 visit(s) today

Newer Post

Thumbnail for Charles River expands US bioanalysis capabilities with US$470M Frontage acquisition

PureHealth to recruit 250 Emirati graduates in UAE healthcare sector by 2028

Older Post

Thumbnail for Charles River expands US bioanalysis capabilities with US$470M Frontage acquisition

Sofinnova Partners closes US$815M crossover fund to back European life sciences companies

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *